Eli Lilly and Company (NYSE:LLY) Trading Down 4.5% – What’s Next?

Eli Lilly and Company (NYSE:LLY) shares fell 4.5% during trading on Thursday . The stock traded as low as $1,153.14 and last traded at $1,155.97. 3,014,422 shares were traded during mid-day trading, a decline of 3% from the average daily volume of 3,117,803 shares. The stock had previously closed at $1,210.02.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly is investing another $750 million to expand U.S. manufacturing capacity for its diabetes and obesity medicines. The Resilience expansion in Ohio is expected to add at least 400 jobs, bringing the site’s workforce above 1,400, and supports the company’s broader plan to spend approximately $55 billion on U.S. manufacturing. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
• Positive Sentiment: The completion of a late-stage retatrutide trial provides a potential next catalyst for Lilly’s obesity and diabetes pipeline. Investors are now awaiting study results, particularly regarding weight loss and possible cardiovascular benefits. Lilly’s Retatrutide Trial Completion Signals Next Wave in Diabetes and Obesity Drugs
• Positive Sentiment: Analyst commentary continues to emphasize Lilly’s growth profile, supported by its expanding obesity and diabetes franchises and a broader pipeline of potential medicines. Jim Cramer characterized LLY as a long-term “own, don’t trade” stock, while brokerages maintain a consensus “Moderate Buy” rating. Jim Cramer: Eli Lilly Is A Good Company
• Neutral Sentiment: Lilly’s planned $2.8 billion acquisition of AtaiBeckley would add exposure to psychedelic drug development, but the transaction is still an early-stage pipeline investment and is unlikely to materially affect near-term earnings. Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion
• Negative Sentiment: Erste Group Bank lowered its 2026 EPS forecast to $35.34 from $36.33, although the revised estimate remains above the broader consensus of $34.91. The cut may reinforce concerns that Lilly’s elevated valuation requires continued earnings upside. Analyst Earnings Estimate Update
• Negative Sentiment: Pre-earnings analysis cautions that Lilly may not have the strongest combination of estimate revisions and surprise indicators for an upcoming earnings beat, creating near-term pressure despite strong recent revenue and profit growth. Eli Lilly Earnings Expected to Grow

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LLY shares. UBS Group raised their price objective on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Citigroup increased their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Jefferies Financial Group lifted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Finally, Truist Financial increased their target price on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

Eli Lilly and Company Stock Performance

The stock has a market cap of $1.09 trillion, a P/E ratio of 41.06, a PEG ratio of 1.52 and a beta of 0.51. The business has a 50 day moving average price of $1,148.72 and a 200 day moving average price of $1,042.77. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the company earned $3.34 EPS. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. As a group, sell-side analysts expect that Eli Lilly and Company will post 34.91 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LLY. Willner & Heller LLC increased its position in shares of Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after acquiring an additional 9 shares during the period. Tanager Wealth Management LLP increased its holdings in Eli Lilly and Company by 2.6% during the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after purchasing an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC raised its position in Eli Lilly and Company by 1.5% during the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after purchasing an additional 10 shares in the last quarter. Wealthspan Partners LLC lifted its holdings in shares of Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after buying an additional 10 shares during the period. Finally, G&S Capital LLC grew its position in shares of Eli Lilly and Company by 2.0% during the 4th quarter. G&S Capital LLC now owns 501 shares of the company’s stock worth $538,000 after buying an additional 10 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.